Core Laboratories Inc.
CLB
$11.86
$0.252.15%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 523.85M | 522.82M | 513.77M | 511.07M | 509.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 523.85M | 522.82M | 513.77M | 511.07M | 509.79M |
| Cost of Revenue | 420.52M | 415.84M | 405.65M | 403.02M | 399.96M |
| Gross Profit | 103.33M | 106.98M | 108.12M | 108.05M | 109.83M |
| SG&A Expenses | 38.59M | 38.09M | 38.88M | 34.39M | 38.89M |
| Depreciation & Amortization | 14.95M | 15.16M | 15.42M | 15.58M | 15.78M |
| Other Operating Expenses | -2.32M | -2.47M | -1.57M | -841.00K | -1.21M |
| Total Operating Expenses | 471.75M | 466.63M | 458.38M | 452.15M | 453.43M |
| Operating Income | 52.10M | 56.20M | 55.39M | 58.92M | 56.36M |
| Income Before Tax | 46.19M | 45.61M | 40.44M | 43.31M | 41.21M |
| Income Tax Expenses | 14.03M | 18.49M | 16.10M | 5.23M | 4.19M |
| Earnings from Continuing Operations | 32.15 | 27.12 | 24.33 | 38.07 | 37.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -753.00K | -922.00K | -626.00K | -551.00K | -350.00K |
| Net Income | 31.40M | 26.20M | 23.71M | 37.52M | 36.68M |
| EBIT | 52.10M | 56.20M | 55.39M | 58.92M | 56.36M |
| EBITDA | 67.05M | 71.36M | 70.80M | 74.51M | 72.15M |
| EPS Basic | 0.67 | 0.56 | 0.51 | 0.80 | 0.78 |
| Normalized Basic EPS | 0.50 | 0.54 | 0.53 | 0.59 | 0.57 |
| EPS Diluted | 0.66 | 0.55 | 0.49 | 0.78 | 0.76 |
| Normalized Diluted EPS | 0.49 | 0.53 | 0.52 | 0.58 | 0.56 |
| Average Basic Shares Outstanding | 188.46M | 188.25M | 188.02M | 187.78M | 187.56M |
| Average Diluted Shares Outstanding | 191.04M | 190.82M | 190.61M | 190.36M | 190.14M |
| Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Payout Ratio | 5.97% | 7.15% | 7.90% | 4.98% | 5.09% |